Kymera Therapeutics Q2 2024 GAAP EPS $(0.58) Beats $(0.72) Estimate, Sales $25.650M Beat $12.554M Estimate
Portfolio Pulse from Benzinga Newsdesk
Kymera Therapeutics reported Q2 2024 GAAP EPS of $(0.58), beating the estimate of $(0.72). Sales were $25.650M, surpassing the estimate of $12.554M.
August 07, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kymera Therapeutics reported better-than-expected Q2 2024 results with GAAP EPS of $(0.58) beating the $(0.72) estimate and sales of $25.650M surpassing the $12.554M estimate.
The better-than-expected earnings and sales figures are likely to positively impact Kymera Therapeutics' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100